CAESARIA, Israel – IceCure Medical Ltd. (NASDAQ:ICCM), a cryoablation technology company, today announced that it has received notice of approval from the Japan Patent Office for a patent entitled “Cryogen Flow Control.”
The patent, which is expected to remain in effect until 2042, is part of IceCure’s strategy to improve the accuracy and efficiency of cryoablation procedures, a minimally invasive method of destroying tumors by freezing.
The ProSense® system, developed by IceCure, uses liquid nitrogen to freeze and destroy both benign and malignant tumors, including breast, kidney, lung and liver tumors. The system is designed for ease of use and portability, allowing breast tumor procedures to be performed quickly in the office, thereby potentially reducing recovery time, pain and surgical risks for patients.
The newly filed patent focuses on regulating cryogen flow based on sensor data, ensuring that the tips of catheters and probes are consistently maintained at the desired temperature during cryoablation.
This control is critical to the safety of surrounding tissue and the overall success of the procedure. Advanced system features may include support for navigation and patient body mapping, expanding the technology’s potential applications.
Eyal Shamir, CEO of IceCure, expressed confidence that the new patent will play a significant role in advancing the field of cryoablation by enabling more precise navigation and mapping, which could lead to wider clinical applications. The company’s partnership with Terumo, its distributor in Japan, is expected to strengthen IceCure’s presence in the Japanese market.
The patent is still pending approval in other major markets, including the European Union and the United States. IceCure’s intellectual property portfolio currently includes 42 issued and permitted patents, reflecting the company’s commitment to innovation in cryoablation technology.
The information in this article is based on a press statement from IceCure Medical.
This article was created with the help of AI and reviewed by an editor. For more information please see our Terms and Conditions.